Stuart Peterson

Stuart Peterson is cofounder and General Partner with tech-focused venture firm ARTIS Ventures. As their name implies, the ARTIS team has become known within the industry over the past decade for their artisanal approach to venture: a hands-on effort across their entire team with a laser focus on what they believe to be unique, one-of-a-kind, market defining opportunities. More recently, they have received recognition for their willingness and ability to take on deeper science problem sets… Show more

Stuart Peterson is cofounder and General Partner with tech-focused venture firm ARTIS Ventures. As their name implies, the ARTIS team has become known within the industry over the past decade for their artisanal approach to venture: a hands-on effort across their entire team with a laser focus on what they believe to be unique, one-of-a-kind, market defining opportunities. More recently, they have received recognition for their willingness and ability to take on deeper science problem sets ranging from the creation of targeted therapeutics to the interpretation and delivery of genomics-based solutions that expedite diagnosis and improve medical outcomes. According to Mr. Peterson, not enough traditional energy of a venture firm is currently spent tackling big, challenging problems like curing cancer. Instead, too many funds continue to chase incremental progress and short-term gains. Show less

Earlier this month, ARTIS Ventures-backed Stemcentrx charged out of stealth mode with a boom heard across the industry. This small, private South San Francisco biotech company revealed an impressive five investigational drugs in human clinical trials generating positive responses in patients with small cell lung cancer, triple-negative breast cancer, ovarian cancer, and peritoneal cancer. Stemcentrx has two additional drugs beginning Phase I clinical trials, and is growing its pipeline of novel… Show more

Earlier this month, ARTIS Ventures-backed Stemcentrx charged out of stealth mode with a boom heard across the industry. This small, private South San Francisco biotech company revealed an impressive five investigational drugs in human clinical trials generating positive responses in patients with small cell lung cancer, triple-negative breast cancer, ovarian cancer, and peritoneal cancer. Stemcentrx has two additional drugs beginning Phase I clinical trials, and is growing its pipeline of novel targets addressing additional major cancer types.

Early Phase I/II trial results from the company’s lead program are already being hailed as one of the most exciting breakthroughs in small-cell lung cancer in four decades. Lead Investigator M. Catherine Pietanza, M.D. at Memorial Sloan Kettering Cancer Center noted, “The activity of the drug that we have seen is remarkable, and importantly, the durable, long-term responses are notable in such an aggressive disease where progression is normally very rapid.”
Show less